Propanc Biopharma Achieves Over 90% Tumor Growth Inhibition for PRP in PDAC Preclinical Models

With GMP production targeted for late 2026 and a clinical trial application expected in Australia within months, Propanc Biopharma is translating preclinical momentum into a manufacturing and regulatory timeline that will test the company's execution capacity at every stage. New data from orthotopic and patient-derived xenograft models of pancreatic ductal adenocarcinoma show PRP, a fixed-ratio combination of trypsinogen and chymotrypsinogen administered intravenously, achieved greater than 90% mean tumor growth inhibition versus vehicle controls (p < 0.001) and extended median overall survival by more than 2.5-fold in treated animals.

The dataset extends beyond tumor volume reduction. Investigators reported marked suppression of metastatic burden in the liver and peritoneum, significant remodeling of the tumor microenvironment including reduced cancer-associated fibroblast activity and decreased fibrosis, and suppression of epithelial-mesenchymal transition markers. Notably, PRP enhanced sensitivity of chemo-resistant PDAC cells to standard-of-care gemcitabine/nab-paclitaxel, with investigators observing improved efficacy at lower chemotherapy doses, a finding with direct implications for tolerability design in the planned Phase 1b study.

For QA directors and regulatory leads tracking early-stage oncology candidates, the manufacturing readiness picture is specific: Propanc has stated GMP production is targeted for late 2026, with pharmacokinetics assay validation underway. A memorandum of understanding with Avance Clinical is in place to support CRO execution for the approximately 30–40 patient Phase 1b first-in-human study in advanced solid tumors, with PDAC as a primary focus indication. The FDA previously granted Orphan Drug Designation to PRP for pancreatic cancer, a designation that carries implications for clinical trial design, exclusivity, and regulatory pathway planning.

Translational support comes from limited compassionate-use experience with related proenzyme formulations, which Propanc reports showed a favorable safety profile and signals of prolonged survival in advanced solid-tumor patients. These data are not from a controlled trial, and their weight in the eventual clinical trial application to Australian regulators will depend on how comprehensively they are documented and contextualized within the submission package.

Further study details are expected to be presented at an upcoming scientific meeting, with the company's stated priority being the fastest possible initiation of the Phase 1b trial and subsequent advancement into proof-of-concept studies.

The measurable checkpoint ahead is GMP batch release in late 2026, which will determine whether the clinical trial application timeline holds.

Source: Propanc Biopharma, Inc. via GlobeNewswire, August 6, 2026.